← Back to Search

Diagnostic Test

Multiparametric MRI for Fabry Cardiomyopathy (FIESTA-MRI Trial)

Led By Kate Hanneman
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with Fabry disease
Age ≥ 18 years
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights
No Placebo-Only Group

FIESTA-MRI Trial Summary

This trial will test whether using MRI to map the heart can help doctors detect abnormalities in patients with Fabry disease and identify those at risk for serious problems.

Who is the study for?
This trial is for adults over 18 with Fabry disease, aiming to detect early heart issues. It's not suitable for those who've had a heart attack or can't undergo MRI scans due to health risks or implanted medical devices.Check my eligibility
What is being tested?
The study tests if advanced cardiac MRI techniques can spot early signs of heart damage in Fabry patients and predict future complications better than traditional methods.See study design
What are the potential side effects?
Cardiac MRI is generally safe but may cause discomfort, anxiety, or claustrophobia. Rarely, allergic reactions to contrast agents used during the scan can occur.

FIESTA-MRI Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have Fabry disease.
I am 18 years old or older.

FIESTA-MRI Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Major Adverse Cardiac Events (MACE)
Secondary outcome measures
The FAbry STabilization indEX (FASTEX) score

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

FIESTA-MRI Trial Design

1Treatment groups
Experimental Treatment
Group I: Cardiac MRI, ECG and Blood BiomarkersExperimental Treatment1 Intervention
Additional sequences will be performed during routine clinical cardiac MRI and additional blood samples will be collected during routine blood work.

Find a Location

Who is running the clinical trial?

Alberta Health servicesOTHER
156 Previous Clinical Trials
647,986 Total Patients Enrolled
IRCCS Policlinico S. DonatoOTHER
86 Previous Clinical Trials
129,320 Total Patients Enrolled
Libin Cardiovascular Institute of AlbertaOTHER
3 Previous Clinical Trials
398 Total Patients Enrolled

Media Library

Cardiac MRI (Diagnostic Test) Clinical Trial Eligibility Overview. Trial Name: NCT04856059 — N/A
Fabry Disease Research Study Groups: Cardiac MRI, ECG and Blood Biomarkers
Fabry Disease Clinical Trial 2023: Cardiac MRI Highlights & Side Effects. Trial Name: NCT04856059 — N/A
Cardiac MRI (Diagnostic Test) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04856059 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the uppermost cap on enrollment for this experiment?

"Affirmative. According to clinicaltrials.gov, this research endeavor is still accepting participants and was first announced on June 15th 2021 before being updated most recently on August 19th 2022. It seeks 250 individuals from one single medical centre."

Answered by AI

Is there presently an opportunity for participants to join this experiment?

"Affirmative. Clinicaltrials.gov reveals that this medical experiment, which was first posted on June 15th 2021, is actively recruiting for 250 participants across one site."

Answered by AI
~129 spots leftby Dec 2026